

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40  
minutes  
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source  
(CS) field  
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  
NEWS 5 AUG 24 CA/Caplus enhanced with legal status information for  
U.S. patents  
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in  
CAS REGISTRY  
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM  
thesaurus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 16:10:32 ON 19 OCT 2009

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 16:10:45 ON 19 OCT 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 OCT 2009 HIGHEST RN 1188905-91-0  
DICTIONARY FILE UPDATES: 18 OCT 2009 HIGHEST RN 1188905-91-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s dmxaa

L1 3 DMXAA

=> d l1 1-3

L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN

RN 853799-58-3 REGISTRY

ED Entered STN: 05 Jul 2005

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, mixt. with  
2-[(2,6-dichlorophenyl)amino]benzeneacetic acid (9CI) (CA INDEX NAME)

OTHER NAMES:

CN DMXAA-diclofenac mixture

MF C17 H14 O4 . C14 H11 C12 N O2

CI MXS


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 117570-53-3


CMF C17 H14 O4



CM 2


CRN 15307-86-5

CMF C14 H11 C12 N O2



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 129095-08-5 REGISTRY  
ED Entered STN: 31 Aug 1990  
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, sodium salt (1:1) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, sodium salt (9CI)  
OTHER NAMES:  
CN DMXAA sodium salt  
MF C17 H14 O4 . Na  
CI COM  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, IMPATENTS, IMSRESEARCH, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
CRN (117570-53-3)




● Na

6 REFERENCES IN FILE CA (1907 TO DATE)  
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 117570-53-3 REGISTRY  
ED Entered STN: 18 Nov 1988  
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)  
OTHER NAMES:  
CN 5,6-Dimethyl-9-oxo-9H-xanthen-4-ylacetic acid  
CN 5,6-Dimethylxanthene-4-acetic acid  
CN AS 1404  
CN ASA 404  
CN DMXAA  
CN NSC 640488  
CN Vadimezan  
MF C17 H14 O4  
CI COM  
SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

196 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
196 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s gemcitabine  
L2 11 GEMCITABINE

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 17.33 17.55

FILE 'CAPLUS' ENTERED AT 16:11:09 ON 19 OCT 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Oct 2009 VOL 151 ISS 17  
FILE LAST UPDATED: 18 Oct 2009 (20091018/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

substance identification.

=> s 11

L3 197 L1

=> s 12

L4 5378 L2

=> s 11 and 12

197 L1

5378 L2

L5 6 L1 AND L2

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 6 DUP REM L5 (0 DUPLICATES REMOVED)

=> d 16 1-6 ibib abs

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 2009:739059 CAPLUS

DOCUMENT NUMBER: 151:86657

TITLE: Combinations of therapeutic agents comprising vascular disrupting agent such as 5,6-dimethylxanthenone-4-acetic acid, for treating cancer

INVENTOR(S): Evans, Dean Brent; Jacques, Christian J.

PATENT ASSIGNEE(S): Novartis A.-G., Switz.

SOURCE: PCT Int. Appl., 57pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009076170	A2	20090618	WO 2008-US85535	20081204
WO 2009076170	A3	20090730		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2007-13335P P 20071213

AB The invention relates to a combination comprising vascular disrupting agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a pharmaceutically acceptable salt, ester or prodrug thereof; and one or more pharmaceutically active agents; pharmaceutical compns. comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a com. package comprising said combination. Thus, the effects of 5,6-dimethylxanthenone-4-acetic acid (Compound A), trastuzumab and paclitaxel are evaluated for their antitumor activity using the BT-474 human breast ductal carcinoma xenograft model; the data shows that Compound A at 20 mg/kg given i.v. on days 1, 5 and 9 is

able to produce inhibition of tumor growth; paclitaxel combined with trastuzumab is also active resulting in a combination effect; when Compound A at 20 mg/kg is combined with paclitaxel and trastuzumab, increased activity is apparent resulting in tumor regressions; using the Clark Combination Index method, synergy is indicated; the tolerability of the triple combinations is no worse than that observed when Compound A is dosed alone.

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1250046 CAPLUS

DOCUMENT NUMBER: 149:448110

TITLE: Preparation of Iso CA-4 and analogs as potent cytotoxic agents and inhibitors of polymerization of tubulin

INVENTOR(S): Alami, Mouad; Brion, Jean-Daniel; Provot, Olivier; Peyrat, Jean-Francois; Messaoudi, Samir; Hamze, Abdallah; Giraud, Anne; Bignon, Jerome; Bakala, Joanna; Liu, Jian-Miao

PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique, Fr.

SOURCE: PCT Int. Appl., 78pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent




LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008122620	A1	20081016	WO 2008-EP54118	20080404
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
FR 2914640	A1	20081010	FR 2007-54280	20070404
PRIORITY APPLN. INFO.:			FR 2007-54280	A 20070404
OTHER SOURCE(S):	MARPAT 149:448110			

GI



AB Isocombretastatin A-4 and analogs I [R1, R2, R3 = methoxy (possibly substituted by one or more fluorine atoms); R5 = R6 = hydrogen or fluorine; A = ring chosen from (un)substituted aryls and heteroaryls].

The process for the preparation of I comprises: (a) reaction of acetophenone derivative II with an organometallic compound, A-M [M = alkali metal or earth alkaline metal substituted with a halogen]; and (b) reaction of the resulting phenylethanol derivative III with an acid to form I. Thus, Iso-CA-4 [I; A = C6H3OH-3-OMe-4, R1 = R2 = R3 = OMe, R4 = R5 = R6 = H (IV)] was prepared from 3,4,5-trimethoxyacetophenone (II; R1 = R2 = R3 = OMe, R4 = R5 = R6 = H) via reaction in PhMe with tert-butyl(5-lithio-2-methoxyphenoxy)dimethylsilane [prepared from tert-butyl(5-iodo-2-methoxyphenoxy)dimethylsilane via lithiation with Me3CLi in hexane], dehydration of III with p-toluenesulfonic acid in CH2Cl2, and desilylation with K2CO3 in MeOH. The cytotoxic activity of IV was determined [IC50 = 2-4 nM vs. HCT116; IC50 = 5 nM vs. K562 cells; IC50 = 2 nM vs. B16F10 cells; IC50 = 8 nM vs. U87 cells; IC50 = 8 nM vs. A549 cells; IC50 = 4.5 nM vs. M435 cells; IC50 = 4 nM vs. M231 cells; IC50 = 2.2 µM vs tubulin polymerization].

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)  
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:473431 CAPLUS

DOCUMENT NUMBER: 148:463206

TITLE: oncolytic viruses and antiangiogenic agents in the  
treatment of cancer

INVENTOR(S): Karrasch, Matthias; Mescheder, Axel

PATENT ASSIGNEE(S): Medigene AG, Germany

SOURCE: PCT Int. Appl., 69pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008043576	A1	20080417	WO 2007-EP8930	20071015
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 2073823	A1	20090701	EP 2007-819001	20071015
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			

PRIORITY APPLN. INFO.: US 2006-851598P P 20061013  
WO 2007-EP8930 W 20071015

AB The invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy. Intraarterial infusions of oncolytic virus NV1020 to a patient with progressive metastatic colorectal adenocarcinoma followed by CPT-11 plus cetuximab resulted in stabilization of the disease at 6 mo post treatment.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:984120 CAPLUS  
 DOCUMENT NUMBER: 143:279360  
 TITLE: Methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor  
 INVENTOR(S): Penning, Maarten Tjerk; Van den Broek, Sebastiaan Johannes Jacobus; Voest, Emile Eugene; Beerepoot, Laurens Victor; Mehra, Niven  
 PATENT ASSIGNEE(S): Primagen Holding B. V., Neth.; UMC Utrecht Holding B. V.  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
EP 1725679	A1	20061129	EP 2005-710924	20050302
EP 1725679	B1	20090603		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 432997	T	20090615	AT 2005-710924	20050302
US 20070077578	A1	20070405	US 2006-514345	20060831
US 20090098563	A1	20090416	US 2008-284203	20080919
PRIORITY APPLN. INFO.:			EP 2004-75686	A 20040302
			US 2004-549450P	P 20040302
			EP 2005-710924	A 20050302
			WO 2005-NL155	W 20050302
			US 2006-514345	B1 20060831
AB	This invention provides methods of detecting CD133 antigen (AC133) expression level and use as a biomarker for human cancer diagnosis and therapy monitor. Blood anal. including number of circulating endothelial cells and expression levels of human genes AC133 (CD133), EST032 and U1A evaluated by NASBA anal., were determined prior to and during chemotherapy using drugs such as angiostatin or PrimMed01, gemcitabine, and cisplatin, for a wide range of human tumor types. A use of a nucleic acid mol. comprising at least part of a sequence of AC133 or an analog thereof for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid mol.			
REFERENCE COUNT:	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		



L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:975665 CAPLUS

DOCUMENT NUMBER: 143:264929

TITLE: Methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases

INVENTOR(S): Penning, Maarten Tjerk; Beerepoot, Laurens Victor; Van Den Broek, Sebastiaan Johannes Jacobus; Mehra, Niven; Voest, Emile Eugene

PATENT ASSIGNEE(S): Primagen Holding B.V., Neth.; UMC Utrecht Holding B.V.

SOURCE: Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1725679	A1	20061129	EP 2005-710924	20050302
EP 1725679	B1	20090603		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 432997	T	20090615	AT 2005-710924	20050302
PRIORITY APPLN. INFO.:			EP 2004-75686	A 20040302
			US 2004-549450P	P 20040302
			WO 2005-NL155	W 20050302

AB The invention provides methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases. AC133 antigen mRNA may be quantitated by PCR, RT-PCR, NASBA, SDA, TMA, bDNA or rolling circle amplification. Diseases include cancer and heart disease, high blood pressure, ischemia, stroke, psoriasis, Crohn's disease, rheumatoid arthritis, endometriosis, atherosclerosis, obesity, diabetes mellitus, diabetic retinopathy, macular degeneration, Alzheimer's disease, Peutz Jegher's syndrome, multiple sclerosis, systemic lupus erythematosus, Wegener's granulomatosis, vasculitis, sickle cell disease, thalassemia and angina.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:202462 CAPLUS

DOCUMENT NUMBER: 138:226761

TITLE: Synergistic anticancer combinations containing

INVENTOR(S): 5,6-dimethylxanthenone-4-acetic acid  
 PATENT ASSIGNEE(S): Wilson, William Robert; Siim, Bronwyn Gae  
 SOURCE: Cancer Research Technology Limited, UK  
 PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020259	A2	20030313	WO 2002-GB4025	20020903
WO 2003020259	A3	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2458459	A1	20030313	CA 2002-2458459	20020903
AU 2002324143	A1	20030318	AU 2002-324143	20020903
AU 2002324143	B2	20070913		
EP 1423105	A2	20040602	EP 2002-758562	20020903
EP 1423105	B1	20081203		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012258	A	20041019	BR 2002-12258	20020903
JP 2005509599	T	20050414	JP 2003-524567	20020903
CN 1708296	A	20051214	CN 2002-817257	20020903
NZ 531045	A	20060831	NZ 2002-531045	20020903
EP 1759694	A2	20070307	EP 2006-77049	20020903
EP 1759694	A3	20090218		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI			
NZ 546573	A	20070531	NZ 2002-546573	20020903
CN 1994287	A	20070711	CN 2006-10151393	20020903
NZ 554093	A	20080731	NZ 2002-554093	20020903
AT 415963	T	20081215	AT 2002-758562	20020903
ES 2321283	T3	20090604	ES 2002-758562	20020903
NO 2004000591	A	20040430	NO 2004-591	20040210
ZA 2004001078	A	20050415	ZA 2004-1078	20040210
US 20040204480	A1	20041014	US 2004-790943	20040302
MX 2004002004	A	20050217	MX 2004-2004	20040302
IN 2004CN00684	A	20060113	IN 2004-CN684	20040402
AU 2007202083	A1	20070531	AU 2007-202083	20070509
AU 2007202083	B2	20090820		
US 20080070847	A1	20080320	US 2007-830650	20070730
US 20080070848	A1	20080320	US 2007-830659	20070730
US 20080070886	A1	20080320	US 2007-830668	20070730
US 20080070849	A1	20080320	US 2007-830677	20070730
IN 2008CN02044	A	20090911	IN 2008-CN2044	20080424
AU 2009202760	A1	20090730	AU 2009-202760	20090708
PRIORITY APPLN. INFO.:			GB 2001-21285	A 20010903
			AU 2002-324143	A3 20020903
			CN 2002-817257	A3 20020903
			EP 2002-758562	A3 20020903
			WO 2002-GB4025	W 20020903

US 2004-790943	A1 20040302
IN 2004-CN684	A3 20040402
AU 2007-202083	A3 20070509

AB The present invention relates to synergistic combinations of the 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compds., Vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have antitumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compds. containing the combinations. The antitumor activity and host toxicity of DMXAA/cytotoxic drug combinations was assessed by varying the dose of chemotherapeutic drug up to the toxicity limit, with co-administration of a fixed DMXAA dose (80 µmol/kg, ca. 80% of MTD), and evaluating subsequent tumor growth delay. Of the 7 drugs investigated, 4 (doxorubicin, 5-fluorouracil, cyclophosphamide and cisplatin) had appreciable activity against this tumor as indicated by dose-response relationships providing significant slopes by linear regression, and highly significant growth delays of 10 days at their MTDs.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file medline embase biosis  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
19.00	36.55

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.92	-4.92

CA SUBSCRIBER PRICE

FILE 'MEDLINE' ENTERED AT 16:12:08 ON 19 OCT 2009

FILE 'EMBASE' ENTERED AT 16:12:08 ON 19 OCT 2009

Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:12:08 ON 19 OCT 2009

Copyright (c) 2009 The Thomson Corporation

=> s ll<chem>

SmartSELECT INITIATED

New TRANSFER and ANALYZE Commands Now Available  
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.21	39.76

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-4.92

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 16:12:14 ON 19 OCT 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

SET SMARTSELECT ON  
SET COMMAND COMPLETED

SEL L1 1- CHEM  
L7 SEL L1 1- CHEM : 12 TERMS

SET SMARTSELECT OFF  
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.08	54.84
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.92

FILE 'MEDLINE' ENTERED AT 16:12:14 ON 19 OCT 2009

FILE 'EMBASE' ENTERED AT 16:12:14 ON 19 OCT 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:12:14 ON 19 OCT 2009  
Copyright (c) 2009 The Thomson Corporation

S L7  
L8 661 L7

=> s l8 and (?cancer? or ?tumor? or ?tumeur? or ?neoplasm?)  
L9 630 L8 AND (?CANCER? OR ?TUMOR? OR ?TUMEUR? OR ?NEOPLASM?)

=> s l9 and pd<20020903  
2 FILES SEARCHED...  
L10 255 L9 AND PD<20020903

=> s l10 and (potentiat? or ?enhanc? or ?increas?)  
L11 161 L10 AND (POTENTIAT? OR ?ENHANC? OR ?INCREAS?)

=> s l11 and (gemcitabine or antimetabolite)  
L12 0 L11 AND (GEMCITABINE OR ANTIMETABOLITE)

=> d his

(FILE 'HOME' ENTERED AT 16:10:32 ON 19 OCT 2009)

FILE 'REGISTRY' ENTERED AT 16:10:45 ON 19 OCT 2009  
L1 3 S DMXAA  
L2 11 S GEMCITABINE

FILE 'CAPLUS' ENTERED AT 16:11:09 ON 19 OCT 2009  
L3 197 S L1  
L4 5378 S L2  
L5 6 S L1 AND L2  
L6 6 DUP REM L5 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:12:08 ON 19 OCT 2009

FILE 'REGISTRY' ENTERED AT 16:12:14 ON 19 OCT 2009  
SET SMARTSELECT ON

L7 SEL L1 1- CHEM : 12 TERMS  
SET SMARTSELECT OFF

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:12:14 ON 19 OCT 2009  
L8 661 S L7  
L9 630 S L8 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)  
L10 255 S L9 AND PD<20020903  
L11 161 S L10 AND (POTENTIAT? OR ?ENHANC? OR ?INCREAS?)  
L12 0 S L11 AND (GEMCITABINE OR ANTIMETABOLITE)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.61	58.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.92

STN INTERNATIONAL LOGOFF AT 16:14:36 ON 19 OCT 2009